Recently reported mature survival data have confirmed the favorable prognosis in
polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger …

Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal
expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or …

Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by
exuberant red cell production leading to a broad range of symptoms that compromise quality …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Polycythaemia vera (PV) is a chronic blood cancer; its clinical features are dominated by
myeloproliferation (erythrocytosis, often leucocytosis and/or thrombocytosis) and a tendency …

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm associated with JAK2
mutations (V617F or exon 12) in almost all cases. The World Health Organization has …

Polycythemia vera (PV) is mainly characterized by elevated blood cell counts, thrombotic as
well as hemorrhagic predisposition, a variety of symptoms, and cumulative risks of fibrotic …

Polycythemia vera (PV) is a clonal disorder characterized by unwarranted production of red
blood cells. In the majority of cases, PV is driven by oncogenic mutations that constitutively …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …